Log in

Rhythm Pharmaceuticals Stock Forecast, Price & News

-1.98 (-6.50 %)
(As of 09/17/2020 12:00 AM ET)
Today's Range
Now: $28.46
50-Day Range
MA: $23.19
52-Week Range
Now: $28.46
Volume245,772 shs
Average Volume249,348 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More
Rhythm Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RYTM



Sales & Book Value

Annual SalesN/A
Book Value$6.40 per share


Net Income$-140,730,000.00


Market Cap$1.26 billion
Next Earnings Date11/6/2020 (Estimated)
-1.98 (-6.50 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

How has Rhythm Pharmaceuticals' stock been impacted by COVID-19?

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RYTM stock has increased by 89.7% and is now trading at $28.46.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Rhythm Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rhythm Pharmaceuticals

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Rhythm Pharmaceuticals

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced its quarterly earnings data on Monday, August, 3rd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.83) by $0.12.
View Rhythm Pharmaceuticals' earnings history

What price target have analysts set for RYTM?

7 Wall Street analysts have issued 1 year target prices for Rhythm Pharmaceuticals' shares. Their forecasts range from $18.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $33.71 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals

Who are some of Rhythm Pharmaceuticals' key competitors?

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), Kadmon (KDMN), Amarin (AMRN), Exelixis (EXEL), Myovant Sciences (MYOV), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT) and Crispr Therapeutics (CRSP).

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:
  • Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
  • Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
  • Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
  • Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
  • Mr. Simon D. Kelner, Chief HR Officer (Age 46)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (5.60%), Vanguard Group Inc. (4.47%), MPM Asset Management LLC (4.33%), Marshall Wace North America L.P. (0.68%), Bank of America Corp DE (0.58%) and Charles Schwab Investment Management Inc. (0.48%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan, Ra Capital Management, LP and Todd Foley.
View institutional ownership trends for Rhythm Pharmaceuticals

Which major investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, MPM Asset Management LLC, Goldman Sachs Group Inc., Swiss National Bank, and Jane Street Group LLC. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, Ra Capital Management, LP, and Todd Foley.
View insider buying and selling activity for Rhythm Pharmaceuticals

Which major investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Vanguard Group Inc., Bank of America Corp DE, Mangrove Partners, Bessemer Group Inc., Athanor Capital LP, Charles Schwab Investment Management Inc., and ProShare Advisors LLC.
View insider buying and selling activity for Rhythm Pharmaceuticals

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $28.46.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $1.26 billion. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.